312 related articles for article (PubMed ID: 32909947)
1. Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy.
Cui X; Ma C; Vasudevaraja V; Serrano J; Tong J; Peng Y; Delorenzo M; Shen G; Frenster J; Morales RT; Qian W; Tsirigos A; Chi AS; Jain R; Kurz SC; Sulman EP; Placantonakis DG; Snuderl M; Chen W
Elife; 2020 Sep; 9():. PubMed ID: 32909947
[TBL] [Abstract][Full Text] [Related]
2. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.
Kiyokawa J; Kawamura Y; Ghouse SM; Acar S; Barçın E; Martínez-Quintanilla J; Martuza RL; Alemany R; Rabkin SD; Shah K; Wakimoto H
Clin Cancer Res; 2021 Feb; 27(3):889-902. PubMed ID: 33257429
[TBL] [Abstract][Full Text] [Related]
3. Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma.
Simonds EF; Lu ED; Badillo O; Karimi S; Liu EV; Tamaki W; Rancan C; Downey KM; Stultz J; Sinha M; McHenry LK; Nasholm NM; Chuntova P; Sundström A; Genoud V; Shahani SA; Wang LD; Brown CE; Walker PR; Swartling FJ; Fong L; Okada H; Weiss WA; Hellström M
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083417
[TBL] [Abstract][Full Text] [Related]
4. Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions.
Maghrouni A; Givari M; Jalili-Nik M; Mollazadeh H; Bibak B; Sadeghi MM; Afshari AR; Johnston TP; Sahebkar A
Int Immunopharmacol; 2021 Apr; 93():107403. PubMed ID: 33581502
[TBL] [Abstract][Full Text] [Related]
5. Local Targeting of NAD
Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
[TBL] [Abstract][Full Text] [Related]
6. Tumor-associated microenvironment, PD-L1 expression and their relationship with immunotherapy in glioblastoma, IDH-wild type: A comprehensive review with emphasis on the implications for neuropathologists.
Broggi G; Angelico G; Farina J; Tinnirello G; Barresi V; Zanelli M; Palicelli A; Certo F; Barbagallo G; Magro G; Caltabiano R
Pathol Res Pract; 2024 Feb; 254():155144. PubMed ID: 38277747
[TBL] [Abstract][Full Text] [Related]
7. Combination immunotherapy strategies for glioblastoma.
Chan HY; Choi J; Jackson C; Lim M
J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
[TBL] [Abstract][Full Text] [Related]
8. Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma.
Shu C; Li Q
Crit Rev Oncol Hematol; 2020 Jul; 151():102965. PubMed ID: 32442903
[TBL] [Abstract][Full Text] [Related]
9. An
Zhang Z; Liu L; Ma C; Cui X; Lam RHW; Chen W
Small Methods; 2021 Jun; 5(6):. PubMed ID: 34423116
[TBL] [Abstract][Full Text] [Related]
10. PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential.
Yang T; Kong Z; Ma W
Hum Vaccin Immunother; 2021 Feb; 17(2):546-553. PubMed ID: 32643507
[TBL] [Abstract][Full Text] [Related]
11. Immune landscape-based machine-learning-assisted subclassification, prognosis, and immunotherapy prediction for glioblastoma.
Li H; He J; Li M; Li K; Pu X; Guo Y
Front Immunol; 2022; 13():1027631. PubMed ID: 36532035
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
Antonios JP; Soto H; Everson RG; Moughon D; Orpilla JR; Shin NP; Sedighim S; Treger J; Odesa S; Tucker A; Yong WH; Li G; Cloughesy TF; Liau LM; Prins RM
Neuro Oncol; 2017 Jun; 19(6):796-807. PubMed ID: 28115578
[TBL] [Abstract][Full Text] [Related]
13. Current state and future of co-inhibitory immune checkpoints for the treatment of glioblastoma.
Shen S; Chen L; Liu J; Yang L; Zhang M; Wang L; Zhang R; Uemura Y; Wu Q; Yu X; Liu T
Cancer Biol Med; 2020 Aug; 17(3):555-568. PubMed ID: 32944390
[TBL] [Abstract][Full Text] [Related]
14. Assessing personalized responses to anti-PD-1 treatment using patient-derived lung tumor-on-chip.
Veith I; Nurmik M; Mencattini A; Damei I; Lansche C; Brosseau S; Gropplero G; Corgnac S; Filippi J; Poté N; Guenzi E; Chassac A; Mordant P; Tosello J; Sedlik C; Piaggio E; Girard N; Camonis J; Shirvani H; Mami-Chouaib F; Mechta-Grigoriou F; Descroix S; Martinelli E; Zalcman G; Parrini MC
Cell Rep Med; 2024 May; 5(5):101549. PubMed ID: 38703767
[TBL] [Abstract][Full Text] [Related]
15. The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy.
Desland FA; Hormigo A
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027976
[TBL] [Abstract][Full Text] [Related]
16. Recruiting T-Cells toward the Brain for Enhanced Glioblastoma Immunotherapeutic Efficacy by Co-Delivery of Cytokines and Immune Checkpoint Antibodies with Macrophage-Membrane-Camouflaged Nanovesicles.
Xu X; Zhang Z; Du J; Xue Y; Chen X; Zhang J; Yang X; Chang D; Xie J; Ju S
Adv Mater; 2023 Jun; 35(25):e2209785. PubMed ID: 37101060
[TBL] [Abstract][Full Text] [Related]
17. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
[TBL] [Abstract][Full Text] [Related]
18. Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment.
Wu A; Maxwell R; Xia Y; Cardarelli P; Oyasu M; Belcaid Z; Kim E; Hung A; Luksik AS; Garzon-Muvdi T; Jackson CM; Mathios D; Theodros D; Cogswell J; Brem H; Pardoll DM; Lim M
J Neurooncol; 2019 Jun; 143(2):241-249. PubMed ID: 31025274
[TBL] [Abstract][Full Text] [Related]
19. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
[TBL] [Abstract][Full Text] [Related]
20. Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer.
Zhang L; Chen Y; Wang H; Xu Z; Wang Y; Li S; Liu J; Chen Y; Luo H; Wu L; Yang Y; Zhang H; Peng H
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34140315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]